|Articles|July 3, 2013

Cost Aside, Rheumatoid Arthritis Drugs Have Similar Effect

Rheumatoid arthritis patients who were treated with a more costly treatment, saw no more improvement than those sought conventional treatment in reducing time off work.

Rheumatoid arthritis patients who were treated with a more costly treatment, saw no more improvement than those sought conventional treatment in reducing time off work. US News reports:

Treatment with a pricey biological drug was no better than cheaper, conventional therapy in terms of reducing time off from work for people with rheumatoid arthritis, a new study finds.

Swedish researchers assessed lost work days among rheumatoid arthritis patients who had not responded to initial treatment with a standard medication, methotrexate.

The group of 204 patients were randomly given either the biological drug infliximab (Remicade) or conventional combination therapy with the non-biologics sulfasalazine plus hydroxychloroquine.

Read the full story here: http://bit.ly/12Bc1hh

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text